B+
Bull case
20%
Probability
Target price
$33.00
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
TYRA
Tyra BiosciencesFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
A reproducible, durable SURF302 response with acceptable chronic-dosing safety could support the planned adjuvant Phase 3 path; favorable BEACH301 data would add a distinct indication. TYRA reported $353.9 million of cash, equivalents and marketable securities at Q2 2026.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
A disappointing BEACH301 growth or safety signal could weaken the achondroplasia opportunity. [#SEC-8K-2026-08-04]
Momentum
16
Value
41
Sentiment
42
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $19.00 · Bull $33.00 · Bear $9.00Analysis 2026-10-26; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-11-05 • Vendor: Data Vendor v1
Scores
As of 2026-11-05 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-26 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-11-05
Investment thesis
As of 2026-11-05
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-11-05. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $47.45
Why
Momentum16 · Δ7d +7.0
Value41 · Δ7d -0.0
Sentiment42 · Δ7d -0.2
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • A disappointing BEACH301 growth or safety signal could weaken the achondroplasia opportunity. [#SEC-8K-2026-08-04]
- • SURF302 efficacy rests on small early cohorts; response durability and Phase 3 reproducibility are unresolved. [#PR-EARNINGS-2026-09-09]
- • SURF302's small early cohorts may overstate later efficacy, while durability, optimal dose, Phase 3 design and achondroplasia benefit remain unproven.
Catalyst clock
2027-01-24
SURF302 dose and Phase 3 development decisions
Lead driver: Value · See fundamentals
Momentum
16
18% active weight
Current posture
7d trendImproving
Δ7d
+7.0
Δ21d
+8.8
Value
41
43% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.2
Sentiment
42
39% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-52.3
Why this grade
Composite grade F. Momentum 16.5 / Value 40.6 / Sentiment 41.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-26. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$19.00
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$9.00
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-11-05
Fundamentals (TTM)
As of 2026-11-05
Market Cap
$1.44B
Beta
1.07
Shares Out
59.68M
P/E (TTM) · Derived
-12.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-13.58
Rev YoY
-
EPS YoY
+46.3%
Gross Margin
-
Op Margin
-
Net Debt
-$250.19M
Current Ratio
14.91
As of 2026-11-05 • Updated nightlySource: Internal modelMethods & Data